Join Futurist Eric Fry for The Road to AGI Summit

A secretive, controversial AI development could soon reinvent the world we live in. Eric Fry shows you where to move your money before it’s too late.

Thu, August 22 at 1:00PM ET
 
 
 
 
Reserve Your Spot

Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

The Real Value of Novavax Lies in Its Pipeline, Not the Pandemic

By Chris Markoch, InvestorPlace Contributor
NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.

Virgin Galactic Struggles to Stay in Orbit Above $50

By Will Ashworth, InvestorPlace Contributor
Virgin Galactic announced June 25 that FAA was good with full commercial launch. SPCE stock blasted off and fell back to earth. Where to next?

Orphazyme A/S May Look Like a Long Shot, but Things Aren’t That Dire

By Thomas Niel, InvestorPlace Contributor
How far could ORPH stock climb if it gets squeezed? Maybe not back above $77 per share. But, a move back to $15-$20 per share could be attainable. For investors with a healthy risk appetite, and a stomach for volatility, consider it a buy at today's prices (around $7.25 per share).

The Outlook for Ocugen Stock Has Deteriorated Further

By Larry Ramer, InvestorPlace Contributor
Phase 3 data on Covaxin wasn't outstanding, and there are indications that demand for additional vaccines in the U.S. and Canada will be low for some time. OCGN remains a good stock to short.

Workhorse Stock Did Great in June, But It’s a Risky Buy

By Will Ashworth, InvestorPlace Contributor
It might be tempting to look at the recent hype for WKHS stock and jump on board, but the company's future is unsure for now.

Near-Doubled Revenues Show High Tide Is a Canna-Biz Contender

By Louis Navellier and the InvestorPlace Research Staff
You might find a hidden gem in the retail marijuana niche with HITI stock, as it should move higher due to a value-added acquisition.

Consider AST SpaceMobile Stock a Worthwhile Moonshot

By Thomas Niel, InvestorPlace Contributor
Risk remains high, as its technology could fail to deliver, sending shares cratering towards zero. There may only be a moderate chance of hitting its long-term projections. Even so, hopping into ASTS stock now, after its pop, but while it's still on the launching pad, may be a high risk worth taking.

Long-Term Investors Should Buy Nvidia Stock on Weakness

By Chris Markoch, InvestorPlace Contributor
Traders may not like NVDA stock, but it still looks like a sound long-term investment. Nvidia's outlook depends on one's objective.

3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory

By Alex Sirois, InvestorPlace Contributor
OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward.

Investors Need to Give Stem Stock Time to Ripen

By Ian Bezek, InvestorPlace Contributor
Stem is a compelling play on the green energy revolution. Just don't count on STEM stock for short-term gains.

Are Chamath Palihapitiya’s 4 New Biotech SPACs Worth a Look?

By Faizan Farooque, InvestorPlace Contributor
In Chamath Palihapitiya's latest SPAC empire-building move, his four new new biotech SPACs in the genomics and biotech space are making waves.

No Matter How ‘Techy’ Tractor Maker Deere Might Seem, It’s No Tech Stock

By Dana Blankenhorn, InvestorPlace Contributor
DE stock rolled over after the equipment maker recorded a strong April quarter and hiked its dividend. But there’s a limited opportunity for Deere & Company's fancy tractors and combines.

Don’t Play the Ocugen Stock Short Squeeze Before You Read This Warning!

By Josh Enomoto, InvestorPlace Contributor
While the contrarian bullish argument for OCGN stock has picked up considerable chatter, this is an extremely risky trade.

Reality Is Setting in for Overvalued and Debt-Ridden Carnival Corporation

By Muslim Farooque, InvestorPlace Contributor
CCL stock has sold-off this past month, but is still overvalued as investors have become more wary of its dreadful outlook.

JPMorgan Chase Is an OK If Fading Investment in Old Guard Money

By Dana Blankenhorn, InvestorPlace Contributor
JPMorgan Chase is buying fintech companies to protect its wealth management business but it can't catch them all.

Are You Prepared to Take a Long Voyage With Carnival Cruise Lines?

By Chris Markoch, InvestorPlace Contributor
CCL stock looks to have a higher floor, but with revenue figures still unclear, growth investors will need to be in for the long haul.

NVAX Stock Is Not For The Faint Of Heart

By Joel Baglole, InvestorPlace Contributor
On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was 100% effective against severe versions of Covid-19. The Gaithersburg, Maryland-based company now says it will file for "Emergency Use Authorization" of its vaccine with the U.S. Food and Drug Administration (FDA).

The MindMed Psychedelic Revolution Will Take Years to Come to Fruition

By Alex Sirois, InvestorPlace Contributor
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.

Despite Encouraging News, Lordstown’s Shares Still Look Poised to Plunge

By Larry Ramer, InvestorPlace Contributor
With Lordstown still lacking "binding" orders and facing a cash crunch, RIDE stock is likely to tumble sooner or later.
Load More Articles